LivaNova (LIVN) Expected to Announce Earnings on Wednesday

Key Points

• LivaNova (LIVN) is set to release its Q2 2025 earnings report on August 6th, with analysts forecasting earnings of $0.84 per share and revenue of $332.20 million.
• The stock has seen positive movement recently, opening at $43.99 and experiencing a 1.2% increase.
• Rating agencies have shown varying outlooks, with an average target price of $59.29, indicating a general sentiment of "buy" among analysts.

LivaNova (NASDAQ:LIVN - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect LivaNova to post earnings of $0.84 per share and revenue of $332.20 million for the quarter.

LivaNova Stock Down 2.5%

Shares of LivaNova stock traded down $1.06 during trading on Friday, reaching $41.13. The company had a trading volume of 800,401 shares, compared to its average volume of 602,376. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -10.06 and a beta of 0.92. The firm's fifty day moving average is $44.64 and its 200-day moving average is $42.89. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.37 and a current ratio of 1.58. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $57.35.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of LIVN. Strs Ohio acquired a new stake in LivaNova during the first quarter worth about $130,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock worth $1,394,000 after acquiring an additional 1,360 shares during the period. Intech Investment Management LLC increased its stake in shares of LivaNova by 19.6% in the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company's stock valued at $1,724,000 after purchasing an additional 7,195 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of LivaNova by 10.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company's stock valued at $6,633,000 after purchasing an additional 15,405 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company's stock valued at $32,012,000 after purchasing an additional 36,094 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LIVN shares. Robert W. Baird upped their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Tuesday, May 13th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a research note on Tuesday, May 20th. Finally, Barclays cut their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and a consensus price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.